Bob Carter, Belmont, MA (US); Jeng-Shin Lee, Lincoln, MA (US); Szofia S. Bullain, Tustin, CA (US); and Richard C. Mulligan, Cambridge, MA (US)
Assigned to Children's Medical Center Corporation, Boston, MA (US); The General Hospital Corporation, Boston, MA (US); and President and Fellows of Harvard College, Cambridge, MA (US)
Filed by Children's Medical Center Corporation, Boston, MA (US); The General Hospital Corporation, Boston, MA (US); and President and Fellows of Harvard College, Cambridge, MA (US)
Filed on Mar. 4, 2019, as Appl. No. 16/291,829.
Application 16/291,829 is a continuation of application No. 15/619,917, filed on Jun. 12, 2017, granted, now 10,259,862.
Application 15/619,917 is a continuation of application No. 14/239,687, granted, now 9,701,731, issued on Jul. 11, 2017, previously published as PCT/US2012/051412, filed on Aug. 17, 2012.
Claims priority of provisional application 61/525,278, filed on Aug. 19, 2011.
Prior Publication US 2019/0292239 A1, Sep. 26, 2019
1. A method of treating an angiogenic disease or disorder, comprising administering to a subject in need thereof a vector comprising a polynucleotide encoding a chimeric VEGF-binding protein comprising the amino acid sequence of SEQ ID NO: 3.